ALK and non-small cell lung carcinoma: This real-world, retrospective, observational study evaluating pembrolizumab as a first-line treatment for advanced NSCLC patients with a PD-L1 score ≥ 50% and without sensitizing EGFR mutations or ALK translocations, showed a PFS of 9.4 months (95% CI, 6.6 to 11.2).